skip to Main Content

Frontline NALIRIFOX Regimen Shows Promising Activity, Tolerability in Pancreatic Cancer

Frontline NALIRIFOX Regimen Shows Promising Activity, Tolerability in Pancreatic Cancer
The regimen of liposomal irinotecan plus 5-fluorouracil (5-FU)/leucovorin plus oxaliplatin (NALIRIFOX) demonstrated a tolerable safety profile with promising antitumor activity when used as frontline treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), according to updated data from a phase 1/2 study presented during the 2020 ESMO World Congress on Gastrointestinal Cancer Virtual Meeting.

Safety results showed that treatment-related, treatment-emergent adverse events (TEAEs) of grade 3 or higher reported in 68.8% of patients (n = 22), and the most commonly reported toxicities included neutropenia (31.3%), febrile neutropenia (12.5%), and hypokalemia (12.5%). Notably, no patients in the pooled population who received a 50 mg/m2 and 60 mg/m2 dose of the regimen experienced treatment-related grade 3 or higher peripheral neuropathy or fatigue. Read more . . . 


Back To Top